Rsv and bronchiolitis
Pro Research Analysisby 
Searched over 200M research papers
Respiratory Syncytial Virus (RSV) and Bronchiolitis: A Comprehensive Overview
Introduction to RSV and Bronchiolitis
Respiratory Syncytial Virus (RSV) is a leading cause of bronchiolitis, particularly in infants and young children. Bronchiolitis is characterized by the inflammation and obstruction of the small airways in the lungs, leading to symptoms such as wheezing and difficulty breathing 56. RSV is notably the most common viral agent responsible for bronchiolitis, often resulting in hospitalizations among previously healthy infants 56.
RSV-Induced Bronchiolitis and Long-Term Respiratory Issues
Risk of Wheeze and Asthma
RSV-induced bronchiolitis has been linked to an increased risk of recurrent wheeze and asthma later in childhood. Studies have shown that children who suffer from RSV bronchiolitis are more likely to develop wheezing and asthma compared to those who do not experience such infections 139. For instance, a quantitative review indicated that up to 40% of children with RSV bronchiolitis reported wheezing within five years of the initial illness, compared to only 11% in the control group . Additionally, the risk of developing asthma and allergic sensitization by age seven is significantly higher in children who had severe RSV bronchiolitis in infancy .
Comparison with Other Viruses
While RSV is a major cause of bronchiolitis, other viruses like rhinovirus (RV) also play a significant role. Recent studies suggest that RV-induced bronchiolitis may be an even stronger risk factor for recurrent wheeze and asthma than RSV-induced bronchiolitis . This highlights the importance of considering multiple viral etiologies when evaluating long-term respiratory outcomes in children.
Severity and Clinical Management of RSV Bronchiolitis
Severity of RSV-A vs. RSV-B
Research has shown that the severity of bronchiolitis can vary depending on the RSV subtype. For example, RSV-A infections are associated with more severe outcomes, such as a higher need for intensive care and respiratory support, compared to RSV-B infections . This distinction is crucial for clinical evaluation and healthcare planning, especially during RSV season.
Treatment and Prevention Strategies
Currently, the treatment for RSV bronchiolitis is primarily supportive, as no pharmacologic treatments have been proven to significantly improve outcomes . However, passive immunoprophylaxis with monoclonal antibodies against RSV can prevent severe bronchiolitis in high-risk children, such as those born prematurely or with chronic lung disease . Additionally, vaccines for RSV are under development, which could potentially reduce the incidence and severity of RSV bronchiolitis in the future .
RSV in Special Populations
Lung Transplant Recipients
RSV infection poses a significant risk for lung transplant recipients, often leading to bronchiolitis obliterans syndrome (BOS). A Phase 2b trial demonstrated that ALN-RSV01, a small interfering RNA targeting RSV replication, can reduce the incidence of BOS when administered early in the course of RSV infection . This finding underscores the importance of early intervention and targeted therapies in vulnerable populations.
Global Epidemiology
The burden of RSV varies globally, with higher positivity rates observed in hospitalized children compared to outpatients. The seasonality of RSV also differs by region, peaking in winter in temperate countries and during the rainy season in tropical countries . Understanding these epidemiological patterns is essential for effective surveillance and prevention strategies.
Conclusion
RSV is a predominant cause of bronchiolitis in young children, leading to significant short-term and long-term respiratory issues, including an increased risk of wheeze and asthma. While supportive care remains the mainstay of treatment, advancements in immunoprophylaxis and vaccine development hold promise for better management and prevention of RSV bronchiolitis. Continued research and tailored clinical approaches are vital to mitigate the impact of this common yet severe respiratory infection.
Sources and full results
Most relevant research papers on this topic
The role of respiratory syncytial virus‐ and rhinovirus‐induced bronchiolitis in recurrent wheeze and asthma—A systematic review and meta‐analysis
Rhinovirus-induced bronchiolitis is a stronger risk factor for recurrent wheeze and asthma in children than RSV-induced bronchiolitis.
ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients.
ALN-RSV01 reduces the risk of bronchiolitis obliterans syndrome (BOS) after respiratory syncytial virus infection in lung transplant recipients, confirming earlier findings.
DOI